Reference : Inhibitors of cannabinoid receptors and glucose metabolism.
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/5182
Inhibitors of cannabinoid receptors and glucose metabolism.
English
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Paquot, Nicolas mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
2008
Current Opinion in Clinical Nutrition & Metabolic Care
Lippincott Williams & Wilkins
11
4
505-11
Yes (verified by ORBi)
International
1363-1950
London
United Kingdom
[en] Animals ; Blood Glucose/metabolism ; Diabetes Mellitus, Type 2/drug therapy ; Endocannabinoids/physiology ; Humans ; Obesity/drug therapy ; Piperidines/therapeutic use ; Pyrazoles/therapeutic use ; Receptor, Cannabinoid, CB1/antagonists & inhibitors/physiology ; Receptors, Cannabinoid/antagonists & inhibitors/physiology
[en] PURPOSE OF REVIEW: Abdominal obesity is closely related to type 2 diabetes and overactivity of the endocannabinoid system. The present review aims at evaluating the role of endocannabinoid system in glucose dysregulation and the effects of cannabinoid 1 receptor blockade on glucose metabolism in both animal models and overweight/obese humans, especially with type 2 diabetes. RECENT FINDINGS: Cannabinoid 1 receptors have been identified not only in the brain, but also in the adipose tissue, the gut, the liver, the skeletal muscle and even the pancreas, all organs playing a key role in glucose metabolism and type 2 diabetes. Rimonabant, the first selective cannabinoid 1 receptor blocker in clinical use, has been shown to reduce body weight, waist circumference, glycated haemoglobin, triglycerides, insulin resistance index, and to increase HDL cholesterol and adiponectin concentrations in patients with type 2 diabetes, confirming data on nondiabetic overweight/obese patients. Almost half of the metabolic changes, including glycated haemoglobin reduction, could not be explained by weight loss, in agreement with direct peripheral effects. SUMMARY: Cannabinoid 1 blockade reduces food intake and body weight and improves metabolic regulation beyond just weight loss. Because of its positive effect on glucose metabolism, rimonabant deserves consideration in the treatment of overweight/obese patients with type 2 diabetes.
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/5182
10.1097/MCO.0b013e3282fcea11
http://www.co-clinicalnutrition.com
the definitive version is available in Current Opinion in Clinical Nutrition & Metabolic Care. 11(4):505-511, July 2008.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
CB1 antagonists Metabolism 2008.pdfAuthor postprint556.18 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.